Clinical trials: Viraemia
Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission
CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant
This phase II trial studies how well multi-peptide CMV-modified vaccinia Ankara (CMV-MVA Triplex) vaccination of stem cell donors works in preventing cytomegalovirus (CMV) viremia in participants with blood cancer undergoing…
- Conditions
- Accelerated Phase CML, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Lymphocytic Leukemia
- Trial name
- NCT03560752
- Testing
- Multi-peptide CMV-Modified Vaccinia Ankara Vaccine
- Where
- United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Cytomegalovirus Infections, CMV
Cytomegalovirus Risk in Seropositive Kidney Transplant Recipients Stratified by Quantiferon-CMV
To evaluate the Quantiferon-CMV test ability to predict occurrence of cytomegalovirus (CMV) disease o treated infection after kidney transplantation.
- Conditions
- Cytomegalovirus Infections, CMV, Kidney Transplant Infection
- Trial name
- NCT03858907
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- University of Sao Paulo General Hospital
HIV Infections
A Study to Monitor Patients With Primary or Early HIV Infection
The purpose of this study is to monitor patients who recently have been infected with HIV in order to learn how their immune systems respond to HIV infection and to study how the virus acts in their bodies.
- Trial name
- NCT00000911
- Where
- United States
- Volunteers
- 1,500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1-infection, ART
Ph1 Study of FT538 Alone and With Vorinostat for Persistent Low-Level HIV Viremia
This is a single center Phase I clinical trial of FT538 administered intravenously (IV) once every 14 days for 4 consecutive doses for the reduction of the HIV reservoir in lymphoid tissue of HIV-infected individuals receiving…
- Conditions
- HIV-1-infection, ART, Cd4+ Lymphocyte Deficiency, Lymphoid Tissue; Infection
- Trial name
- NCT05700630
- Testing
- FT538, Vorinostat
- Where
- United States
- Sponsor
- Masonic Cancer Center, University of Minnesota
Epstein-Barr Viraemia, Hematologic Diseases
Methyl-qPCR : a New Predictive Marker for Epstein-Barr Virus-associated Lymphoproliferations During Allogeneic Hematopoietic Stem Cell Transplantation
Scientific context Epstein-Barr virus has a causal role in the pathogenesis of multiple distinct lymphomas. Post-transplant lymphoproliferative diseases (PTLD) are the most frequent EBV-induced proliferations.
- Conditions
- Epstein-Barr Viraemia, Hematologic Diseases, Allogeneic Disease
- Trial name
- EBVALLO (NCT03343834)
- Testing
- biological collection
- Where
- France
- Volunteers
- 138 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV Antiretroviral Therapy (ART) Adherence, PMTCT
Optimizing Prevention and Care for Pregnant and Postpartum Adolescent Girls and Young Women With HIV in Tanzania
The goal of this clinical trial is to find better ways to care for pregnant and postpartum adolescent girls and young women (AGYW) aged 15-24 years with HIV in Tanzania, and to prevent them from passing HIV to their babies.
- Conditions
- HIV Antiretroviral Therapy (ART) Adherence, PMTCT, Pregnancy, Retention in Care
- Trial name
- ENGAGE (NCT06605053)
- Testing
- Co-produced intervention to optimize PMTCT care engagement
- Where
- 2 sites in Tanzania
- Volunteers
- 222 people
- Sponsor
- Karolinska Institutet
Kidney Diseases, Kidney Transplant Infection
Reduction of BK Viremia in Kidney Transplant Patients
Reduction of BK Viremia by treating kidney transplant patients.
- Conditions
- Kidney Diseases, Kidney Transplant Infection, Kidney Transplant; Complications
- Trial name
- CP026 (NCT04984902)
- Testing
- Extracorporal therapy
- Where
- Germany
- Sponsor
- ExThera Medical Europe BV
Chronic Hepatitis B
The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment
The goal of this observational study is to explore the efficacy and safety of Tenofovir Amibufenamide (TMF) in Entecavir (ETV) treated chronic hepatitis B patients with low-level viraemia.
- Trial name
- POWER (NCT05755776)
- Testing
- TMF
- Where
- 13 sites in China
- Volunteers
- 204 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
HIV Infection
Interferon Alpha 2b Intensification in HIV-Positive Individuals on Antiretroviral Therapy
Background: Antiretroviral therapy (ART) has been able to improve the lifespan of individuals infected with human immunodeficiency virus type 1 (HIV-1), but ART requires continuous treatment that has substantial consequences on…
- Trial name
- NCT01295515
- Testing
- Pegylated Interferon Alpha 2b (PEGINTRON)
- Where
- 2 sites in United States
- Volunteers
- 7 people
- Sponsor
- National Cancer Institute (NCI)
Kidney Transplantation, Cytomegalovirus Infections, EBV Infection
Is Valacyclovir Non-inferior to Valganciclovir as CMV and EBV Prophylaxis in Kidney Transplant Recipients? A Single-Center Prospective Randomized Pilot Study
Opportunistic CMV viremia (primary infection or reactivation) is usually managed by taking prophylactic medication for both adult and pediatric kidney transplant patients.
- Conditions
- Kidney Transplantation, Cytomegalovirus Infections, EBV Infection, Antiviral Prophylaxis
- Trial name
- NCT07294547
- Testing
- Valacyclovir (Valtrex), Valganciclovir (Valcyte)
- Where
- Taiwan
- Volunteers
- 80 people
- Sponsor
- National Taiwan University Hospital
Response To Dengue Exposure
Trial to Model Primary, Secondary, and Tertiary Dengue Using a Monovalent Vaccine
Background: Dengue is a disease caused by a virus transmitted by mosquitoes in tropical and subtropical regions. Dengue is a leading cause of hospital stays and death in parts of Asia and Latin America, and outbreaks have…
- Trial name
- NCT05691530
- Testing
- rDEN3Δ30/31-7164
- Where
- United States
- Volunteers
- 127 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV-1-infection
Effect of Dolutegravir Intensification on HIV-1 Reservoirs
Persistent HIV viremia occurs in most ART-treated patients and could arise from reactivation of viral expression from latently-infected cells that constitute the viral latent reservoir (LR) and/or residual ongoing viral…
- Trial name
- EDIT (NCT05351684)
- Testing
- Dolutegravir 50 MG
- Where
- Belgium
- Volunteers
- 20 people
- Sponsor
- University of Liege
HIV-1 Infection, Treatment Resistant Disorders
Management of Participants With Low-level Persistent Viremia (ANRS 161 L-VIR)
Management of participants with low-level persistent viremia
- Conditions
- HIV-1 Infection, Treatment Resistant Disorders, Viremia
- Trial name
- NCT02247687
- Testing
- Protease inhibitor, Isentress® (raltegravir), Counseling arm
- Where
- 20 sites in France
- Volunteers
- 4 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Hematologic Diseases, Stem Cell Transplant Complications
Prospective Survey of CMV, Herpesviruses Infections and Diseases in Allo-HSCT
Prospective observational study of epidemiological surveillance, multicenter, non-profit, spontaneous, Italian with objective to describe the incidence of CMV infections and diseases in adult and pediatric patients undergoing…
- Conditions
- Hematologic Diseases, Stem Cell Transplant Complications, Cytomegalovirus Viremia, Herpesvirus Infection
- Trial name
- CYTOALLOSURVEY (NCT04412811)
- Where
- 50 sites in Italy
- Volunteers
- 1,310 people
- Sponsor
- Gruppo Italiano Trapianto di Midollo Osseo
Hiv, Transmission Vertical
Enhanced Mentor Mother Strategy for Pregnant and Postpartum Women Living With HIV
Mentor Mothers (MMs) are peer supporters who help pregnant and postpartum women living with HIV (WLHIV) as they receive prevention of mother-to-child transmission of HIV (PMTCT) services in resource-limited settings like Kenya.
- Conditions
- Hiv, Transmission Vertical, Viremia, Adherence, Treatment
- Trial name
- PIE-eMMs (NCT06999928)
- Testing
- Enhanced Mentor Mother Strategy
- Where
- Kenya
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Indiana University
Acute Leukemia, CMV Viremia
The Molecular Mechanism of CMV-driven NKG2C+NK Cell Expansion in Human
This is an observation study to investigate the molecular mechanism of NKG2C+NK cell expansion after HCMV infection
- Conditions
- Acute Leukemia, CMV Viremia, Hematopoietic Stem Cell Transplantation
- Trial name
- NCT04298502
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
HIV Infection
"OK 2004 Study" (Only Kaletra 2004 Study): Study to Evaluate Suspending Nucleosides From Triple-Drug Therapy in HIV Subjects
Lopinavir/ritonavir monotherapy may maintain virologic suppression in patients who have been undetectable for six months while on triple drug antiretroviral therapy.
- Trial name
- NCT00114933
- Testing
- Stopping nucleosides and continuing lopinavir/ritonavir monotherapy
- Where
- 28 sites in Spain
- Volunteers
- 200 people
- Sponsor
- Arribas, Jose R., M.D.
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV Infections
Evaluating the Safety and Efficacy of Romidepsin in Combination With Antiretroviral Therapy in HIV-Infected Adults With Suppressed Viral Load
Antiretroviral therapy (ART) can reduce HIV to very low levels in the blood, but it cannot cure HIV infection because a small amount of virus remains in cells as a hidden (latent) form.
- Trial name
- NCT01933594
- Testing
- Romidepsin
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART
GV-TH-01 is an open label Phase 1 study of 9 HIV-1 infected adults with suppressed viremia who started anti-retroviral therapy (ART) within 18 months of a negative HIV antibody test. This study has 3 phases.
- Trial name
- NCT01378156
- Testing
- JS7 plasmid DNA and MVA62B vaccine
- Where
- 3 sites in United States
- Volunteers
- 9 people
- Sponsor
- GeoVax, Inc.